Rhabdomyolysis in a Cyclosporine-treated Renal Transplant Recipient Who Received Atorvastatin as Replacement for Fluvastatin.
- Author:
Wan Bok LEE
1
;
Jin Woo PARK
;
Min Soo SONG
;
Moo Yong PARK
;
Young Kwan CHO
;
Bo Yong JEUNG
;
Hyo Wook GIL
;
Jong Oh YANG
;
Eun Young LEE
;
Sae Yong HONG
Author Information
1. Department of Internal Medicine, Soon Chun Hyang University Cheonan Hospital, Cheonan, Korea. eylee@sch.ac.kr
- Publication Type:Case Report
- Keywords:
Rhabdomyolysis;
Atorvastatin;
Cyclosporine;
Fluvastatin
- MeSH:
Cyclosporine;
Cytochrome P-450 Enzyme System;
Drug Interactions;
Humans;
Hydroxymethylglutaryl-CoA Reductase Inhibitors;
Incidence;
Lovastatin;
Rhabdomyolysis*;
Simvastatin;
Transplantation*;
Atorvastatin Calcium
- From:Korean Journal of Nephrology
2004;23(5):836-839
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Statin-induced rhabdomyolysis is a frequent complication in renal transplant recipients receiving cyclosporine, but incidences are different between different types of statins. Statins have different pharmacokinetic properties. Atorvsatatin, simvastatin, lovastatin, and cerivastatin are all metabolized by the cytochrome P450 isoenzyme 3A4 and co-administration of cyclosporine which may inhibit cytochrome P450 isoenzyme 3A4, increases statin levels and therefore increases the risk of rhabdomyolysis. Fluvastatin is metabolized by cytochrome P450 isoenzyme 2C9 and no clinically significant interactions with cyclosporine have been reported. Atorvastatin with co-administration of cyclosporine in renal transplant patients may induce drug interactions, therefore we recommend the routine monitoring of muscle enzymes, in these cases. Here, we reported a case of rhabdomyolysis in a patient who received atorvastatin and cyclosporine with the review of the literature.
